Polish blood banks counting on Ortho Clinical Diagnostics
The newest laboratory system from Ortho Clinical Diagnostics is a big success: 32 VITROS 3600 immunoassay systems are going to be used in 15 of a total of 21 blood banks in Poland in the future. They will enable roughly 800,000 blood tests to be carried out each year. This next-generation diagnosis platform is based on VITROS technologies, the best in the world, thus meeting the demands of modern clinical laboratories and providing patients and hospitals alike with high-quality, reliable test results.
Data on the work routines and positive feedback from 60 clinical laboratories around the world formed the basis for the innovative development of the VITROS® 3600 system. It uses the same reagents as other VITROS® platforms and works to the same high level of precision. For instance, no water connection or drain is required for this compact system, so that the device is flexible enough to fit perfectly into every laboratory work routine.
“We have always considered it our task to provide physicians with aids of the highest quality to ensure optimum treatment and care of all patients. The introduction of the 3600 immunoassay system is one way of carrying on this important task with the next generation of devices, which have a wide-ranging, top-class test menu and the capacity for effective future tests,” said Martina Müller, Managing Director of Ortho Clinical Diagnostics GmbH, responsible for Germany, Poland, Switzerland and Austria. “At Ortho-Clinical Diagnostics, we use our extensive investments in biomarkers for special disease patterns to support the development of progressive medical tests in reproductive health, oncology, cardiology and metabolic diseases.”
The VITROS® 3600 Immunoassay System
The VITROS® 3600 Immunoassay System is conceived for laboratories with medium to high volumes. The VITROS® 3600 System combines three time-tested VITROS® technologies into a single system and thus enables reliable, precise test results for a broad menu of immunoassay tests:
MicroWell™, together with the detection technology of signal-enhanced chemiluminescence, enables unusual test performance for a wide palette of diseases, even with small-volume patient samples.
MicroSensor™ technology is the first immunoassay system to automatically check the index of the sample quality. This saves time and work and also reduces the risk of error, in comparison to manual interpretation.
Intellicheck® verifies the analysis performance and lowers the risk of error by informing the operator and tracking in real time.
Thanks to the system’s processing speed, onboard reagent capacity and uninterrupted operating procedure, laboratories can cope with peak periods and lower turnaround time.
20.11.2009
